CL2017003066A1 - Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal - Google Patents

Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal

Info

Publication number
CL2017003066A1
CL2017003066A1 CL2017003066A CL2017003066A CL2017003066A1 CL 2017003066 A1 CL2017003066 A1 CL 2017003066A1 CL 2017003066 A CL2017003066 A CL 2017003066A CL 2017003066 A CL2017003066 A CL 2017003066A CL 2017003066 A1 CL2017003066 A1 CL 2017003066A1
Authority
CL
Chile
Prior art keywords
compositions
inhalation
calcium carbonate
sublingual
administration
Prior art date
Application number
CL2017003066A
Other languages
English (en)
Inventor
Yosef Ben
Yigal Dov Blum
Original Assignee
Amorphical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorphical Ltd filed Critical Amorphical Ltd
Publication of CL2017003066A1 publication Critical patent/CL2017003066A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA COMPOSICIONES QUE COMPRENDEN CARBONATO DE CALCIO AMORFO (ACC), ADECUADAS PARA SER ADMINISTRADAS MEDIANTE INHALACIÓN, Y MÉTODOS PARA SU USO EN EL TRATAMIENTO DE ENFERMEDADES Y AFECCIONES QUE RESPONDEN A ACC. SE PROPORCIONAN ADICIONALMENTE COMPOSICIONES DE ACC ADECUADAS PARA ADMINISTRACIÓN BUCAL O SUBLINGUAL.</p>
CL2017003066A 2015-06-04 2017-12-01 Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal CL2017003066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562170712P 2015-06-04 2015-06-04

Publications (1)

Publication Number Publication Date
CL2017003066A1 true CL2017003066A1 (es) 2018-04-13

Family

ID=57440881

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003066A CL2017003066A1 (es) 2015-06-04 2017-12-01 Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
CL2017003095A CL2017003095A1 (es) 2015-06-04 2017-12-04 Carbonato de calcio amorfo estabilizado con polifosfatos o bisfosfonatos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017003095A CL2017003095A1 (es) 2015-06-04 2017-12-04 Carbonato de calcio amorfo estabilizado con polifosfatos o bisfosfonatos

Country Status (14)

Country Link
US (4) US11052107B2 (es)
EP (2) EP3302505B1 (es)
JP (3) JP7007716B2 (es)
KR (2) KR102833797B1 (es)
CN (3) CN117137872A (es)
AU (3) AU2016273059B2 (es)
BR (1) BR112017026131B1 (es)
CA (2) CA2988068C (es)
CL (2) CL2017003066A1 (es)
ES (1) ES3056807T3 (es)
HK (2) HK1253702A1 (es)
IL (2) IL256065B2 (es)
RU (2) RU2739563C2 (es)
WO (2) WO2016193982A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174828B1 (en) * 2014-07-31 2026-03-25 Amorphical Ltd. Non-aqueous liquid and semi-solid formulations of amorphous calcium carbonate
WO2017125918A1 (en) 2016-01-18 2017-07-27 Amorphical Ltd. Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions
CN108778295A (zh) 2016-01-18 2018-11-09 艾玛菲克有限公司 作为细胞培养基补充剂的稳定的无定形碳酸钙
KR102531595B1 (ko) 2016-10-25 2023-05-11 아모피컬 리미티드 백혈병 치료용 비결정성 탄산칼슘
US11007170B2 (en) 2017-02-02 2021-05-18 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
CN110183876A (zh) * 2019-06-21 2019-08-30 中国矿业大学(北京) 重质碳酸钙改性剂、重质碳酸钙的改性方法、改性重质碳酸钙及其应用
WO2021014448A1 (en) * 2019-07-23 2021-01-28 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance
EP4117685A4 (en) * 2020-03-11 2024-03-20 Amorphical Ltd. AMORPHOUS CALCIUM CARBONATE FOR THE TREATMENT OF ACIDOSIS
KR102428137B1 (ko) * 2020-05-27 2022-08-03 세종대학교산학협력단 칼슘 보충용 조성물
EP4284343A4 (en) * 2021-01-28 2024-12-11 Amorphical Ltd. Particles comprising amorphous divalent metal carbonate
WO2024059842A2 (en) * 2022-09-16 2024-03-21 Augusta University Research Institute, Inc. Compositions and methods of minimizing long covid
WO2025169195A1 (en) * 2024-02-07 2025-08-14 Amorphical Ltd. Methods of increasing sensitivity of bacteria resistant to antibiotics and inhibiting biofilm formation
WO2026014534A1 (ja) * 2024-07-11 2026-01-15 国立大学法人旭川医科大学 間質性膀胱炎・膀胱痛症候群の予防又は治療用医薬組成物
WO2026014535A1 (ja) * 2024-07-11 2026-01-15 国立大学法人旭川医科大学 子宮内膜症の予防又は治療用組成物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
JPS56124368A (en) * 1980-02-25 1981-09-30 Monsanto Co Stabilized amorphous calcium carbonate
EP0052677B1 (en) 1980-11-21 1985-01-09 Monsanto Company Concentrates for the preparation of carbonated beverages
US4964894A (en) 1986-03-31 1990-10-23 Freepons Donald E Plant growth regulators derived from chitin
ATE82120T1 (de) 1987-08-28 1992-11-15 Norwich Eaton Pharma Kalziumzusaetze.
GB2217988B (en) 1988-04-11 1992-04-01 Gould Leonard W Regimen for increasing bone density in humans
EP0345375B1 (en) 1988-06-09 1995-03-22 N.V. Innogenetics S.A. HIV-3 retrovirus and its use
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US5037639A (en) 1989-05-24 1991-08-06 American Dental Association Health Foundation Methods and compositions for mineralizing calcified tissues
US5460803A (en) * 1989-05-24 1995-10-24 American Dental Association Health Foundation Methods and compositions for mineralizing and fluoridating calcified tissues
US6348571B1 (en) 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
JPH099871A (ja) 1995-07-03 1997-01-14 Kita Nippon Shokuhin Kk 菓 子
AU1366697A (en) 1995-12-26 1997-07-28 Holomed Aps A method and system for generating an x-ray image
JPH10236957A (ja) 1997-02-24 1998-09-08 Bankaku Souhonpo:Kk 骨粗鬆症の改善剤
US20060165784A1 (en) 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US20030077604A1 (en) 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
CN1543338B (zh) 2001-08-16 2010-06-16 Cmp医疗有限公司 壳多糖微粒及其医疗用途
US8603514B2 (en) * 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
JP2003292453A (ja) 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
JP2004081739A (ja) 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
US9107751B2 (en) 2002-12-12 2015-08-18 Warsaw Orthopedic, Inc. Injectable and moldable bone substitute materials
US20070207198A1 (en) 2003-09-17 2007-09-06 Beijing Sino-Hong Kong Dafu Science & Technology Of Biowave Co., Ltd. Use Of N-Acety1-D-Glucosamine In The Manufacture Of Medicaments For Anti-Tumors And Anti-Metastasis
GB0324918D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
KR100561231B1 (ko) 2004-05-18 2006-03-15 한국지질자원연구원 표면개질에 의한 비정질 탄산칼슘 제조방법
JP5614916B2 (ja) 2004-05-26 2014-10-29 ベン−グリオン ユニバーシティー オブ ザ ネゲヴ，リサーチ アンド ディベロップメント オーソリティー 安定な非結晶質炭酸カルシウムを含む経口投与可能な組成物
AU2005296271A1 (en) 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
HUE038099T2 (hu) 2004-12-21 2018-09-28 Musc Found For Res Dev Kompozíciók és módszerek sebgyógyulás és szöveti regeneráció elõsegítésére
KR20130036350A (ko) 2004-12-22 2013-04-11 솔베이(소시에떼아노님) 알칼리 토금속 카르보네이트의 내산성 입자
DE102005047807A1 (de) 2005-06-04 2006-12-07 Solvay Infra Bad Hönningen GmbH Modifizierte Nanopartikel
US20070041506A1 (en) 2005-08-22 2007-02-22 Michelle Bottino Digital sensor holder
GB0522045D0 (en) 2005-10-28 2005-12-07 Novartis Ag Pharmaceutical compositions
IL178495A (en) 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
US20080226715A1 (en) 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
ES2393041T3 (es) * 2007-10-22 2012-12-18 Amorphical Ltd. Carbonato de calcio amorfo estable que comprende aminoácidos fosforilados
WO2009087553A1 (en) 2008-01-02 2009-07-16 Aurobindo Pharma Limited Kits for administering bisphosphonates
CN101314031A (zh) 2008-07-14 2008-12-03 王冰 一种改善骨营养的制剂
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
WO2010045558A1 (en) 2008-10-17 2010-04-22 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
WO2010093285A1 (en) * 2009-02-12 2010-08-19 Aduro Material Ab Composition comprising biodegradable carrier for controlled drug delivery
CN101580260B (zh) 2009-05-31 2011-04-27 河南大学 一种微乳液法制备无定形碳酸钙的方法
US8906996B2 (en) 2010-07-30 2014-12-09 Schaefer Kalk Gmbh & Co. Kg Spherical, amorphous calcium carbonate particles
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
CN102085356B (zh) 2010-12-28 2013-02-27 北京同仁堂健康药业股份有限公司 一种用于增加骨密度的组合物及其制备方法
US8936773B2 (en) 2011-04-28 2015-01-20 Calera Corporation Methods and compositions using calcium carbonate and stabilizer
ES2831699T3 (es) * 2011-12-13 2021-06-09 Amorphical Ltd Un carbonato de calcio morfo para el tratamiento de la mala absorción de calcio y los trastornos metabólicos óseos
JP6263181B2 (ja) * 2012-08-07 2018-01-17 アモーフィカル リミテッド． 安定化させた非晶質炭酸カルシウムの製造方法
WO2014122658A1 (en) * 2013-02-11 2014-08-14 Amorphical Ltd. Amorphous calcium carbonate for accelerated bone growth
CN103663532B (zh) * 2013-12-21 2015-10-28 中国科学院上海硅酸盐研究所 一种制备无定形碳酸钙纳米球的方法
RU2550865C1 (ru) 2013-12-30 2015-05-20 Меграбян Казарос Аршалуйсович Способ получения карбоната кальция
EP3174828B1 (en) 2014-07-31 2026-03-25 Amorphical Ltd. Non-aqueous liquid and semi-solid formulations of amorphous calcium carbonate
WO2017125918A1 (en) * 2016-01-18 2017-07-27 Amorphical Ltd. Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions

Also Published As

Publication number Publication date
IL256065A (en) 2018-01-31
US11033576B2 (en) 2021-06-15
EP3302506A4 (en) 2018-12-19
CN117137872A (zh) 2023-12-01
RU2017145305A3 (es) 2019-08-14
AU2016273058A1 (en) 2018-01-18
AU2016273058B2 (en) 2021-05-20
AU2021204073B2 (en) 2023-03-30
JP7360738B2 (ja) 2023-10-13
JP2018516929A (ja) 2018-06-28
CA2988068A1 (en) 2016-12-08
CL2017003095A1 (es) 2018-05-11
RU2017145291A (ru) 2019-07-09
RU2017145291A3 (es) 2019-11-14
AU2016273059B2 (en) 2021-07-15
US20180153930A1 (en) 2018-06-07
IL256065B2 (en) 2024-04-01
US11052107B2 (en) 2021-07-06
HK1253702A1 (zh) 2019-06-28
CN107921061A (zh) 2018-04-17
HK1253701A1 (zh) 2019-06-28
IL256064B2 (en) 2024-04-01
BR112017026125A2 (pt) 2018-08-28
US12115184B2 (en) 2024-10-15
US20180140631A1 (en) 2018-05-24
US20200345763A1 (en) 2020-11-05
RU2017145305A (ru) 2019-07-10
KR102833797B1 (ko) 2025-07-14
EP3302506B1 (en) 2025-10-01
CA2988068C (en) 2024-01-09
AU2016273059A1 (en) 2018-01-18
WO2016193983A1 (en) 2016-12-08
EP3302505C0 (en) 2024-02-28
IL256065B1 (en) 2023-12-01
IL256064A (en) 2018-01-31
EP3302505B1 (en) 2024-02-28
JP7039006B2 (ja) 2022-03-22
US10758565B2 (en) 2020-09-01
EP3302505A4 (en) 2019-02-06
IL256064B1 (en) 2023-12-01
CA2988060A1 (en) 2016-12-08
KR102957815B1 (ko) 2026-04-27
ES3056807T3 (en) 2026-02-24
BR112017026131A2 (pt) 2018-08-28
AU2021204073A1 (en) 2021-07-29
WO2016193982A1 (en) 2016-12-08
CA2988060C (en) 2023-09-05
RU2748976C2 (ru) 2021-06-02
EP3302506A1 (en) 2018-04-11
CN107921060A (zh) 2018-04-17
KR20180057603A (ko) 2018-05-30
EP3302505A1 (en) 2018-04-11
EP3302506C0 (en) 2025-10-01
BR112017026131B1 (pt) 2023-11-21
JP7007716B2 (ja) 2022-01-25
KR20180053632A (ko) 2018-05-23
JP2018516930A (ja) 2018-06-28
RU2739563C2 (ru) 2020-12-25
JP2022046688A (ja) 2022-03-23
US20210308178A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX391624B (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CR20160433A (es) Nuevos compuestos
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
BR112016024176A2 (pt) composições para tratamento bucal tendo estabilidade aprimorada
TW201613578A (en) Pharmaceutical combinations
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях